Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Change in Account Payables (2016 - 2025)

ImmunityBio (IBRX) has disclosed Change in Account Payables for 12 consecutive years, with $979000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Change in Account Payables rose 130.46% to $979000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$190000.0, a 94.0% increase, with the full-year FY2025 number at -$190000.0, up 94.0% from a year prior.
  • Change in Account Payables was $979000.0 for Q4 2025 at ImmunityBio, up from -$1.4 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $6.5 million in Q1 2021 to a low of -$8.9 million in Q3 2024.
  • A 5-year average of -$277500.0 and a median of -$477500.0 in 2022 define the central range for Change in Account Payables.
  • Peak YoY movement for Change in Account Payables: crashed 758.35% in 2023, then skyrocketed 545.81% in 2024.
  • ImmunityBio's Change in Account Payables stood at -$3.5 million in 2021, then skyrocketed by 112.32% to $437000.0 in 2022, then plummeted by 758.35% to -$2.9 million in 2023, then dropped by 11.71% to -$3.2 million in 2024, then skyrocketed by 130.46% to $979000.0 in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Change in Account Payables are $979000.0 (Q4 2025), -$1.4 million (Q3 2025), and -$6.2 million (Q2 2025).